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Background: Recommendations from international task forces on geriatric assessment emphasize the need for
research including validation of cancer-specific geriatric assessment (C-SGA) tools in oncological settings. This study
was to evaluate the feasibility of the SAKK Cancer-Specific Geriatric Assessment (C-SGA) in clinical practice.
Methods: A cross sectional study of cancer patients ≥65 years old (N = 51) with pathologically confirmed
cancer presenting for initiation of chemotherapy treatment (07/01/2009-03/31/2011) at two oncology
departments in Swiss canton hospitals: Kantonsspital Graubünden (KSGR N = 25), Kantonsspital St. Gallen (KSSG
N = 26). Data was collected using three instruments, the SAKK C-SGA plus physician and patient evaluation
forms. The SAKK C-SGA includes six measures covering five geriatric assessment domains (comorbidity,
function, psychosocial, nutrition, cognition) using a mix of medical record abstraction (MRA) and patient
interview. Five individual domains and one overall SAKK C-SGA score were calculated and dichotomized as
below/above literature-based cut-offs. The SAKK C-SGA was evaluated by: patient and physician estimated
time to complete, ease of completing, and difficult or unanswered questions.
Results: Time to complete the patient questionnaire was considered acceptable by almost all (≥96%) patients
and physicians. Patients reported slightly shorter times to complete the questionnaire than physicians
(17.33 ± 7.34 vs. 20.59 ± 6.53 minutes, p = 0.02). Both groups rated the patient questionnaire as easy/fairly easy
to complete (91% vs. 84% respectively, p = 0.14) with few difficult or unanswered questions. The MRA took on
average 8.32 ± 4.72 minutes to complete. Physicians (100%) considered time to complete MRA acceptable,
96% rated it as easy/fairly easy to complete. Individual study site populations differed on health-related
characteristics (excellent/good physician-rated general health KSGR 71% vs. KSSG 32%, p = 0.007). The overall
mean C-SGA score was 2.4 ± 1.12. Patients at KSGR had lower C-SGA scores (2.00 ± 1.19 vs. 2.81 ± 0.90,
p = 0.009) and a smaller proportion (28% vs.65%, p = 0.008) was above the C-SGA cut-off score compared to
KSSG.
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Conclusions: These results suggest the SAKK C-SGA is a feasible practical tool for use in clinical practice. It
demonstrated discriminative ability based on objective geriatric assessment measures, but additional
investigations on use for clinical decision-making are warranted. The SAKK C-SGA also provides important
usable domain information for intervention to optimize outcomes in older cancer patients.
Keywords: Assessment, Cancer-specific geriatric assessment, Decision-making, Geriatric assessment, Older
cancer patients, Older adultsBackground
Cancer is considered an age-related disease of increasing
public health concern due to worldwide aging popula-
tions. The World Health Organization (WHO) reports a
projected continued rise in cancer mortality with an
estimated 13.1 million cancer deaths worldwide in 2030
[1]. The majority of cancer patients presenting for cancer
treatment are older (>65 years old). Older cancer patients
are often diagnosed at later stages, undertreated, and
rarely included in clinical trials [2,3]. In fact, evidence on
cancer treatment is mainly generated in younger cancer
patients. Because aging is an individualized process older
cancer patients represent a heterogeneous group requiring
specific management–an oncological and research chal-
lenge [2,4].
Comprehensive multidimensional geriatric assessment
has been shown in general population studies to be a
promising tool of assessment domains that capture a
range of patient factors resulting in an individualized
intervention-plan for optimizing clinical management
and health outcomes [5-7]. Similarly, cancer-specific
geriatric assessment (C-SGA) with multiple assessment
domains can aid in identifying, managing and potentially
correcting (through intervention) problems that might
specifically interfere with cancer treatment [8,9]. For
over a decade C-SGA has been a growing field of
cancer-related research. Much of the earlier literature
only allowed for analysis of indirect evidence and clinical
opinion supporting the use of C-SGA [10]. More recent
publications include a range of study designs as well as
reviews that have expanded C-SGA specific knowledge.
(for example [11-15]) Moreover, recommendations from
the International Society of Geriatric Oncology (SIOG)
task force on geriatric assessment and the European
Organization for Research and Treatment of Cancer
(EORTC) Elderly Task Force have underscored the need
for additional research including validation of C-SGA
tools in oncological settings. [16,17] Despite growing
evidence additional studies to determine C-SGA’s ability
to predict relevant outcomes such as choice of treat-
ment, treatment tolerance, treatment completion, sur-
vival, quality of life, and comparative effectiveness to
physician judgment are still needed [13,16,18-24]. In-
corporating C-SGA into clinical trials of older cancerpatients could provide such evidence, establish an ob-
jective measure for inclusion into clinical trials, and fur-
ther advance the knowledgebase accelerating translation
of use into evidence-based practice. Evidence from use
of C-SGA in clinical trial settings has been increasing
but does not directly inform on feasibility of implemen-
tation in daily oncological practice [24-26]. In clinical
practice the ease and time to perform a C-SGA is a vital
to whether or not it will be adopted in regular practice
and requires specific investigation.
The Swiss Group for Clinical Cancer Research
(Schweizerische Arbeitsgemeinschaft für Klinische
Krebsforschung [SAKK]) developed the SAKK C-SGA
specifically for use in clinical trials including older
cancer patients as well as daily oncological practice.
The SAKK C-SGA includes six standard geriatric as-
sessment measures covering five geriatric assessment
domains (comorbidity, function, psychosocial, nutri-
tion, and cognition) using a mix of medical record
abstraction (MRA) and patient interview (described in
Table 1). The individual measures are brief, reliable,
valid, and predictive of morbidity and mortality in
geriatric patients [27-33]. The measures have been well
studied in the geriatric-oncology and geriatric assess-
ment literature [34]. The SAKK C-SGA was developed
based on an extensive literature search and expert
clinical advice to be brief and easy to implement in
busy clinical settings (i.e. low physician and patient
burden appropriate for clinical practice as well as cli-
nical trials). The patient questionnaire alone was pre-
viously pilot tested in a small sample (N = 5) of older
cancer patients to judge phrasing and comprehension
in older adults, but the complete SAKK C-SGA has not
been assessed for ease of administration in daily onco-
logical settings. To address this gap the aim of the
current study was to evaluate feasibility and practical
use of the SAKK C-SGA in Swiss clinical practices
caring for older cancer patients.
Methods
The protocol for this study was reviewed and ap-
proved by the Kantonsspital Graubünden (KSGR)
Institutional Review Board (IRB) Ethics Committee
and the Kantonsspital St. Gallen (KSSG) IRB Ethics
Table 1 Content and operationalization of the SAKK cancer-specific geriatric assessment (C-SGA)
Assessment
domain
Assessment tool Number of
questions
How administered Estimated time
required (min)
Range: cut-off
Individual domains
Comorbidity Age-adjusted Charlson Comorbidity
Index (CCI)[27, 28]
18 Medical Record
Abstraction (MRA)
5-10 0-43: ≥4
Function Vulnerable Elders Survey (VES-13) [29] 12 Self-report or Interviewer
Administered
<5 0-10: ≥3
Psychosocial Geriatric Depression Scale 5-item short
form (GDS-5) [30]
5 Self-report or Interviewer <5 0-5: ≥2
Modified MOS- Social Support Survey
(mMOS-SS) [33]
8 Administered <5 0-8: ≤2.5
Nutrition Mini Nutritional Assessment (MNA) [31] 3 Interviewer administered
and MRA
<4 0-14: ≤11
Cognition Mini-Cog [32] 3 Interviewer administered 5 1-3 w/clock draw: 0 or 1–2
w/abnormal clock
SAKK C-SGA
5 Domains Six Measures: CCI, VES-13, GDS-5,
mMOS-SS, MNA, Mini-Cog
22– Patient
20– MRA
Self-report, Interviewer
Administered, MRA
<30 0-5: ≥3
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with all federal regulations governing the protection and
privacy of human subjects, the Helsinki Declaration,
and with the informed consent of the participants.
Study population
We conducted a cross sectional study of older cancer
patients (total study population, N = 51) cared for at two
oncology departments in canton hospitals in Switzerland:
KSGR (N = 25) and KSSG (N= 26). The study population
included a consecutive case series of older adults
(≥65 years old) with physician permission to participate, a
pathologically confirmed cancer diagnosis (newly diag-
nosed or relapsed), presenting for initiation of a new
chemotherapy treatment (first-line or subsequent treat-
ment) between July 2009 and March 2011.
Data collection
Data for this study was collected using three instru-
ments, the SAKK C-SGA plus physician and patient
evaluation forms. The SAKK C-SGA (English, German,
French, Italian) and scoring instructions (English only)
are available by author request.
SAKK C-SGA
The SAKK C-SGA was administered in two parts by
trained study personnel (hereafter referred to as phys-
ician) before the start of chemotherapy treatment. The
interviewer-administered C-SGA patient questionnaire
contained 22-questions with a variety of responses (e.g.
rating scales, yes/no, word recall, clock drawing and
spaces for recording the results of the MRA see Add-
itional file 1). The C-SGA MRA included 20-questionsfor extracting health-related information (height, weight,
comorbidities) from patient medical records.
Patient and physician evaluation forms
The patient evaluation form was filled-out by patients
immediately after completion of the SAKK C-SGA patient
interview. It had a total of 11-questions divided into two
parts: (1) five patient information questions (gender,
marital status, education, nationality, mother tongue); and
(2) six questions relating to the patient questionnaire
(estimated/acceptable time to complete, ease of adminis-
tration, patient reaction, difficult/unanswered questions).
Personnel administering the SAKK C-SGA completed
the physician evaluation immediately after each patient
assessment. The physician questionnaire included 18-
questions divided into four sections: (1) six patient informa-
tion questions (age, general health, type cancer, treatment
approach, life expectancy, performance status); (2) six
questions relating to the C-SGA patient questionnaire
(estimated/acceptable time to complete, ease of admi-
nistration, patient reaction, difficult/unanswered ques-
tions); (3) four questions relating to MRA (estimated time
to complete, ease of conducting, difficulty of obtaining
information, missing information), and (4) two questions
relating to training (years of experience, type of training).
Analytic variables
Socio-demographic characteristics
We categorized information on age (65–69,70-79, 80+
years); gender (male, female); education (compulsory-
up to 10th grade, secondary-high school, teacher
training or vocational diploma; tertiary-undergraduate,
graduate, post-graduate degree); marital status (single,
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Health-related characteristics
Physician-rated general health was assessed by a single
question with five answer likert scale ranging from
“excellent” to “poor”. We also classified information on
type of cancer (bladder, breast, colon, leukemia, lung,
lymphoma, pancreatic, prostate, uterine, other); type of
treatment (curative, palliative), physician judgement of
life expectancy (<1 year, 1-2 years, 3 + years); and WHO
performance score (0–4) with higher scores indicating
worse health [35].
SAKK C-SGA
Table 1 shows content and operationalization of the
SAKK C-SGA and individual domain assesment tools.
SAKK C-SGA scoring was calculated as five individual
domain scores (function, psychosocial, nutrition, cogni-
tion, comorbidity based on the published scoring rules
for individual measures) and one overall C-SGA score.
All scores were based on whole number ranges. The
five individual domain scores were dichotomized as
deficit or not based on literature-based pre-determined
cut-off scores for each measure (see Table 1). Individual
domains with more than one measure (e.g. psycho-
social) were considered to be a deficit if at least one
measure crossed the cut-off. The overall C-SGA score
was calculated by summing the number of individual
domain deficits (range 0–5) and dichotomizing deficits
as ≤2 (fit for standard treatment) vs. ≥3 (unfit for stan-
dard treatment) [11,14].
SAKK C-SGA evaluation
The SAKK C-SGA was assessed by patient and phy-
sician estimated time to complete (mean time, accep-
table yes/no), ease of completing (easy/fairly easy, just
right, hard/very hard), patient reaction (interested, in-
different, rejecting), and difficult or unanswered ques-
tions (yes/no).
Analytic methods
We examined the descriptive characteristics in the
total population and compared the distributions bet-
ween study sites using Student’s t-test for continuous
variables and chi-square or Fisher’s exact tests for
categorical variables testing for statistical significance
in their differences. Similar methods were applied to
results from the patient and physician evaluations.
Associations between C-SGA scores and health-
related characteristics were assessed using Spearman
correlations. All analyses were performed using SAS
(V9.3 SAS Institute, Cary, NC) and all p values were
from two-sided tests.Results
Population characteristics
Table 2 shows the characteristics of the individual study
site populations as well as total study population. Most
of the study population was Swiss (88%) and over half
were aged 70–79 years, male with excellent/good
physician-rated general health. Lung cancer (20%) and
lymphoma (25%) were the most common types of
cancers being treated in the total study population.
The individual study site populations were evenly
distributed (KSGR 49%, KSSG 51%) but differed on
health-related characteristics. KSGR had more patients
with excellent/good (71% vs. 32%, p = 0.007) physician-
rated general health. The majority of KSSG patients
were receiving palliative treatment (88% vs. 52%,
p = 0.006); had a life expectancy of <1 year (61% vs.
19%, p = 0.01); and a WHO performance score of 2
(50% vs. 4%, p = <0.001).
Patient and physician evaluation of the SAKK C-SGA
Table 3 displays the results of patient and physician
evaluation of the SAKK C-SGA. The time to complete
the patient questionnaire was considered acceptable by
almost all patients and physicians. Patients reported
slightly shorter times to complete the questionnaire
than physicians (17.33 ± 7.34 vs. 20.59 ± 6.53 minutes,
p = 0.02). Both groups rated the SAKK C-SGA patient
questionnaire as easy/fairly easy to complete (91% vs.
84% respectively, p = 0.14) with few difficult or un-
answered questions. Physicians reported the MRA took
on average 8.32 ± 4.72 minutes, 100% considered the
time to complete acceptable with 96% rating it as easy/
fairly easy to complete. The majority of personnel ad-
ministering the SAKK C-SGA were nursing staff with
over 11 years of clinical experience (data not shown).
C-SGA characteristics of the study population
Table 4 describes the C-SGA characteristics of the study
population. The overall mean C-SGA score was 2.4 ±
1.12. Patients at KSGR had lower C-SGA scores (2.00 ±
1.19 vs. 2.81 ± 0.90, p = 0.009) and a smaller proportion
(28% vs.65%, p = 0.008) was above the C-SGA cut-off
score compared to KSSG. In the total population the
most common domain deficits were function, nutrition
and comorbidity. By site population KSGR had statisti-
cally significantly fewer patients with a nutrition domain
deficit than KSSG. C-SGA score was correlated with all
health-related characteristics but not with age. Health-
related characteristics differed by C-SGA cut-off scores.
More patients with C-SGA score below the cut-off
had excellent/good physician-rated general health
(67% vs. 32%, p = 0.007); were receiving curative treat-
ment (44% vs. 13%, p = 0.02); and had a WHO per-
formance score of 0 or 1 (85% vs. 58%, p = 0.002).
Table 2 Characteristics of the individual site and total study population
KSGR KSSG Total population
N = 25 N = 26 N = 51
Characteristic n (%) P value*
Socio-demographic
Study site
KSGR 25 (100) – 25 (49)
KSSG – 26 (100) 26 (51)
Age
65–69 years 6 (24) 7 (27) 13 (25) 0.57
70–79 years 15 (60) 12 (46) 27 (53)
80+ years 4 (16) 7 (27) 11 (22)
Gender
Male 17 (68) 11 (42) 28 (55) 0.07
Female 8 (32) 15 (58) 23 (45)
Education
Compulsory 7 (28) 5 (21) 12 (24) 0.60
Secondary 17 (68) 16 (67) 33 (67)
Tertiary 1 (4) 3 (12) 4 (8.2)
Marital status
Single 0 (0) 0 (0) 0 (0) 0.92#
Married 18 (72) 17 (65) 35 (69)
Widowed 7 (28) 7 (27) 14 (27)
Divorced 0 (0) 2 (7.7) 2 (3.9)
Nationality
Swiss 22 (88) 23 (88) 45 (88) 1.00
Other 3 (12) 3 (12) 6 (12)
Health-related
Physician-rated general health
Excellent/good 17 (71) 8 (32) 25 (51) 0.007
Fair 6 (25) 9 (36) 15 (31)
Poor/very Poor 1 (4.1) 8 (32) 9 (18)
Type of cancer
Bladder 1 (4.0) 0 (0) 1 (1.9) 0.40#
Breast 0 (0) 1 (3.8) 1 (1.9)
Colon 6 (24) 0 (0) 6 (12)
Leukemia 0 (0) 7 (27) 7 (14)
Lung 5 (20) 5 (19) 10 (20)
Lymphoma 5 (20) 8 (31) 13 (25)
Pancreatic 0 (0) 1 (3.8) 1 (1.9)
Prostate 3 (12) 1 (3.8) 4 (7.8)
Uterine 0(0) 1 (3.8) 1 (1.9)
Other 5 (20) 2 (7.7) 7 (14)
Type of treatment
Curative 12 (48) 3 (12) 15 (29) 0.006
Palliative 13 (52) 23 (88) 36 (71)
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Table 2 Characteristics of the individual site and total study population (Continued)
Life expectancy
<1 year 4 (19) 16 (61) 20 (42) 0.01
1-2 years 8 (38) 6 (23) 14 (30)
3+ years 9 (43) 4 (15) 13 (28)
WHO performance score
0 15 (60) 4 (15) 19 (37) <0.001
1 9 (36) 9 (35) 18 (35)
2 1 (4.0) 13 (50) 14 (27)
KSGR Kantonsspital Graubünden, KSSG Kantonsspital St. Gallen, WHO World Health Organization.
* Test of difference between study sites.
# Significance test excluding marital status single and cancers with zero cells.
Table 3 Patient and physician evaluation of SAKK cancer-specific geriatric assessment (C-SGA)
Patient N = 51 Physician N = 9
n (%) or mean ± SD P value*
Patient questionnaire
Estimated time to complete
Average time in minutes 17.33 ±7.34 20.59 ±6.53 0.02
Rated time as acceptable 44 (96) 51 (100) 0.22
Ease of completing
Easy/fairly easy 42 (91) 43 (84) 0.14#
Just right 4 (8.7) 3 (5.9)
Hard/very hard 0 (0) 5 (9.8)
Patient reaction §
Interested 37 (73) 44 (86)
Indifferent 7 (14) 5 (9.8)
Rejecting 0 (0) 2 (3.9)
Difficult to answer questions
Yes 5 (11) 8 (16) 0.91
No 39 (89) 43 (84)
Unanswered questions
Yes 6 (14) 11 (22) 0.03
No 38 (86) 40 (78)
Medical record abstraction
Estimated time to complete
Average time in minutes – 8.32 ±4.72
Rated time as acceptable – 50(100)
Ease of completing
Easy/fairly easy – 47 (96)
Just right – 2 (4.1)
Hard/very hard – 0 (0)
C-SGA Cancer-Specific Geriatric Assessment; SD standard deviation.
* Test of difference between patients and physicians.
# Significance test based on two categories created by collapsing the bottom two categories with the smallest cell counts into one (e.g. Easy/Fairly easy vs. Just
right/Hard/Very hard).
§ Significance test not possible due to zero cells.
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Table 4 Cancer-specific geriatric assessment (C-SGA) characteristics in the individual site and total study populations
C-SGA characteristics by study site and total population
KSGR KSSG Total population
N = 25 N = 26 N = 51
n (%) P value*
Mean C-SGA score 2.00 ±1.19 2.81 ±0.90 2.4 ±1.12 0.009
C-SGA over cut-off score
Yes 7 (28) 17 (65) 24 (47) 0.008
No 18 (72) 9 (35) 27 (53)
C-SGA by domain deficits
Function
Yes 14 (56) 18 (69) 32 (63) 0.33
No 11 (44) 8 (31) 19 (37)
Psychosocial
Yes 1 (4.0) 7 (27) 8 (16) 0.05
No 24 (96) 19 (73) 43 (16)
Nutrition
Yes 13 (52) 22 (85) 35 (69) 0.02
No 12 (48) 4 (15) 16 (31)
Cognition
Yes 3 (12) 1 (3.9) 4 (7.8) 0.35
No 22 (88) 25 (96) 47 (92)
Comorbidity
Yes 19 (76) 25 (96) 44 (86) 0.05
No 6 (24) 1 (3.9) 7 (14)
C-SGA association with health-related characteristics
Correlation coefficient P value
Age 0.12 0.43
Physician-rated general health 0.39 0.008
Type of treatment −0.38 0.01
Life expectancy −0.32 0.03
WHO performance score 0.63 <0.0001
Health-related characteristics by C-SGA cut-off score
Below C-SGA cut-off score Above C-SGA cut-off score
N = 27 N = 24
n (%) P value#
Age
65–69 years 8 (30) 5 (21) 0.72
70–79 years 14 (52) 13 (54)
80+ years 5 (18) 6 (25)
Physician-rated general health
Excellent/good 18 (67) 7 (32) 0.007
Fair 8 (30) 7 (32)
Poor/very poor 1 (3.7) 8 (36)
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Table 4 Cancer-specific geriatric assessment (C-SGA) characteristics in the individual site and total study populations
(Continued)
Type of treatment
Curative 12 (44) 3 (13) 0.02
Palliative 15 (56) 21 (87)
Life expectancy
<1 year 7 (30) 13 (54) 0.16
1–2 years 7 (30) 7 (29)
3+ years 9 (39) 4 (17)
WHO performance score
0 16 (59) 3 (12) 0.002
1 7 (26) 11 (46)
2 4 (15) 10 (42)
C-SGA Cancer-Specific Geriatric Assessment, KSGR Kantonsspital Graubünden KSSG Kantonsspital St. Gallen, SD Standard Deviation, WHO World
Health Organization.
* Test of difference between study sites.
# Test of difference between groups by C-SGA cut-off.
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This study demonstrated that the SAKK C-SGA is fea-
sible and easy to implement in daily clinical practice.
The overall time to complete was less than 30 minutes
and considered acceptable by patient and physician alike.
Importantly, most participants rated the SAKK C-SGA
(patient questionnaire and MRA) as easy or fairly easy
to complete. Only a small number of patients or physi-
cians reported questions that were either difficult or un-
answered. This likely reflects real-world patient-specific
difficulties encountered in daily oncological practice as
opposed to problems with the questions themselves.
This is supported by the fact that all measures included
in the SAKK C-SGA are widely used and previously vali-
dated. Plus there was no pattern to the individual ques-
tions that were reported as difficult or unanswered (e.g.
only one question was mentioned twice, questions iden-
tified were not domain-specific).
These findings also suggest that the SAKK C-SGA was
able to objectively discriminate older patients’ health.
The difference in SAKK C-SGA scores between study
sites mirrored differences in the site-specific patient
characteristics. KSGR had an overall healthier popula-
tion (as assessed by other health-related measures) with
a higher proportion of patients being treated for curative
intent than KSSG. Correspondingly, KSGR SAKK C-
SGA scores were lower and a higher proportion was
below the cut-off score (i.e. fit for standard treatment).
In both sites more patients below the cut-off score had
better physician-rated general health, a longer life ex-
pectancy as well as better WHO performance scores.
Interestingly, in this population C-SGA scores were re-
lated to other health measures but not age, underscoring
the potential advantage of C-SGA versus age-based
decision-making. As expected (i.e. health-related measureswere designed to assess unique health states) there was
not complete overlap in how individual health-related
measures and the SAKK C-SGA identified the patient
population. This is similar to findings by other researchers
who found physicians and C-SGA do not identify the
same patient populations as fit/unfit for treatment and
that C-SGA compares with but is not identical to assess-
ments based other health-measures [36-40].
Although shorter screening tools exist and the SAKK
C-SGA had high correlation with other simpler health-
related measures (e.g. WHO performance score) it af-
fords additional clinical benefit to patient and provider
[4,25,40-44]. The time to complete though longer than a
brief screen is suitable for pre-treatment or pre-trial
oncological work-ups. The time to complete the SAKK
C-SGA in daily oncological practice was similar to that
of another C-SGA tool pilot tested in clinical trial set-
tings [25]. It also requires much less time and no referral
for a full comprehensive geriatric assessment. This is par-
ticularly important since not all healthcare systems offer
specialized geriatric care. Second, the SAKK C-SGA iden-
tifies individual domain deficits for intervention acknowl-
edged within the C-SGA literature as having specific
benefits in the care of older cancer patients [2,16,19,45].
The problems identified can be addressed either within
oncological practices and/or by referral depending on
available resources and expertise. For example, engaging
social workers, arranging transportation, or providing
nutritional counseling before start of treatment could be
arranged by staff handling cancer treatment, general
practitioners, or referral to a geriatrician depending on
individual patient needs and care situations.
The key advantage is that such interventions, regard-
less of where they are initiated, may mitigate an older
patient’s risk for poor cancer treatment outcomes and
Clough-Gorr et al. BMC Medical Informatics and Decision Making 2013, 13:93 Page 9 of 11
http://www.biomedcentral.com/1472-6947/13/93increase their quality of life. A recent study in Spain
showed that C-SGA detects more information than
oncological evaluation alone [46]. Another in Canada
found that in 70% of their study patients C-SGA identi-
fied previously unidentified medical problems [47]. In
this Swiss population, over half of our patients were
identified by the SAKK C-SGA as not a risk for poor
outcomes (i.e. below cut-off/fit for standard treatment).
Nevertheless, all but one of these patients had a deficit
in at least one domain that otherwise may not have been
identified by oncological evaluation alone or even a
briefer C-SGA screen. Thus use of the SAKK C-SGA
provides readily usable information that can improve
outcomes for patients above or below the cut-off with-
out delay (i.e. no additional assessment necessarily re-
quired). However, we did find that when dementia was
present the SAKK C-SGA (like any geriatric assessment)
was challenging to administer. In patients with dementia
(especially advanced cases) decision-making regarding
treating cancer is likely not be aided by objective C-SGA
measurement. But instead will require a more complex
individualized process between patient-physician-family/
caregiver.
Other researchers in the field and SIOG have identified
the need for shorter C-SGA tools applicable for busy clin-
ical oncology settings [48]. The SAKK C-SGA has several
benefits directly addressing this need. First, assessment
using the SAKK C-SGA requires much less time than a
full geriatric assessment and does not require referral to a
specialist or geriatrics training to administer. Second,
using standard geriatric assessment tools in key domains
the SAKK C-SGA maximizes information gathering and
minimizes patient/physician burden. In fact, since the tool
can be administered by any combination of patient
(all but Mini-Cog), trained staff, or physician it is easily
customized to the individual patient and clinical setting.
Lastly, our findings suggest that use of the SAKK C-
SGA is feasible in clinical practice and may be well
suited to determine eligibility for clinical trials based on
patient health instead of chronological age.
A major challenge of C-SGA is to find a balance bet-
ween time to conduct and producing clinically useful in-
formation (i.e. identifying targets for intervention). The
SAKK C-SGA is a step forward in this balancing act but
can be further improved. This study used an electronic
excel-based CCI calculator that made collecting comor-
bidity data and calculating CCI information easier, more
accurate, and immediately available [28]. Based on our
positive experience with the excel-based CCI we decided
that an electronic version of the SAKK C-SGA could
offer similar advantages in clinical practice and clinical
trials. An electronic SAKK C-SGA would make gathe-
ring data more efficient, produce real time results that
can be immediately incorporated into treatment planning,and increase the likelihood of more widespread and uni-
form use. Development is underway and validation and
feasibility studies are planned.
Several strengths and weaknesses of this study should
be considered. The SAKK C-SGA was developed with
input from geriatricians and oncologists specifically for
use in busy oncological and clinical trial settings. The
tool includes only standard psychometrically evaluated
geriatric assessment measures covering previously iden-
tified key domains. The SAKK C-SGA is easy to score
and available in multiple languages. However, the results
of this study are based on a small number of patients in
Switzerland. Thus generalizability of these findings to
other clinical settings and other healthcare systems are
limited. We did not require exact measurement of time
to complete and assume that most patients/physicians
estimated times. However, both the patient and phy-
sician estimates had similar standard deviations and the
perception of time to complete (i.e. estimated time was
acceptable to nearly all) is an important factor in willing-
ness to adopt the tool. The SAKK C-SGA should be
further tested in larger patient samples, a variety of set-
tings, and over longer periods of time to include out-
come data.
Conclusions
In conclusion, these results suggest that the SAKK C-
SGA is a promising tool for use in clinical practice. It
demonstrated discriminative ability based on objective
geriatric assessment measures. It also provides important
clinical information that could be used for interventions
aimed at optimizing outcomes in older cancer patients.
Future studies of SAKK C-SGA reliability, discriminative
ability for clinical decision-making based on treatment
outcomes, accuracy predicting cancer-related outcomes,
ability to improve outcomes, and generalizability are
warranted.
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